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Polycyclic aromatic hydrocarbon @AH) diolepoxides are known to covalently modify serum 
albumin and hemoglobin. Mass spectrometric techniques have proven quite useful in the 
characterization of the site of adductlon on these proteins. To facilitate the study of PAH 
diolepoxide adducted peptides, model peptide adducts of benzolalpyrene-truns-7,Mllydro 
diol-9,10-epoxide [ anti-BaP(9,10)DE] and benzol alanthracene-fmns-8,9-dihydrodiol-lO,ll- 
epoxide [anti-BaA(lO,ll)DE] have been synthesized for the purpose of studying their high 
energy collision-induced dissociation tandem mass spectra. These spectra are dominated by 
ions produced from cleavage of the peptide-adduct bond with charge retention by the 
adducting moiety. Such ions allow for the facile identification of adducted peptides in a 
mixture by use of neutral loss scans. The peptide sequence can still be deduced from the data 
in most cases, and the site of adduction can be determined. For those peptide-adducts in 
which this is not possible, a charged derivative placed at the N-terminus simplifies the 
peptide fragmentation pattern and makes the spectrum more interpretable. (J Am Sot Mass 
Spectrom 1994, 5, 649-654) 
A 
number of polycyclic aromatic hydrocarbon 
@AH) compounds have demonstrated carcino- 
genic activity [l]. They are major petroleum 
constituents and are found in the environment wher- 
ever fossil fuels have been spilled. PAHs are also 
produced during combustion of fossil fuels [Z, 31 and 
are, therefore, sources of air pollution. Gas-phase dis- 
persal has resulted in detectable levels of PAH in areas 
remote from sources of pollution [4]. The effects of 
these compounds are of major human health and envi- 
ronmental concern [5]. 
Once ingested, the PAH is metabolized, predomi- 
nantly in the liver, by the cytochrome I’450 systems 
(for a review see ref 6). This metabolism involves a 
series of reactive intermediates formed by a multistep 
oxidation process. The bulk of the reactive species are 
deactivated by various mechanisms to soluble nonelec- 
trophilic metabolites that are excreted. However, some 
of these species may react with nucleic acids and 
proteins (for a review see ref 7). Reaction of car&o 
gens with DNA generally is believed to be the initiat- 
ing event that results in the formation of tumors. 
Reaction with proteins, on the other hand, is thought 
to be one of the mechanisms whereby a chemical 
exerts its toxic effects on the cell [8]. The reactions of 
Addms reprint requests to Dr. Klaus Biomann, Department of Chem- 
istry, Room 56410, Massachusetts Institute of Technology, Cam- 
bridge, MA 021394307. 
carcinogens with proteins are of interest for studies of 
the basic mechanisms of carcinogen interactions [S] 
and for molecular dosimetry [9, 101. Two pathways 
that result in the metabolic activation of PAH have 
been described in the literature: the diolepoxide path- 
way 1111 and the one-electron oxidation pathway 
[12-141. 
Recently, mass spectrometric techniques were used 
in the identification of covalent benzo[a]pyrene-fruns- 
7,8-dihydrodiol-9,10-epoxide [anti-BaP(9,lO)DEl 
(Structure I) adducts of serum albumin [15] and 
hemoglobin [ 16,171. The collision-induced dissociation 
(CID) mass spectra of tetrapeptides and pentapeptides 
isolated from fluoranthene-hemoglobin (rat) adducts 
were reported and briefly discussed without mass 
spectrometric assignment of the site of attachment of 
the fluoranthene diolepoxide [IS]. The reaction of 
styrene oxide with human hemoglobin was shown by 
CID mass spectrometry to take place at a-His4 and 
@-His-143 [19]. In this case, where the adducting moi- 
ety is relatively small (l-phenyl-l-hydroxy-ethyl), the 
CID spectra are identical to those of the unmodified 
peptide except for a mass shift of 130 u for the frag- 
ments including the modification. However, large 
polycyclic aromatic adduct moieties have a dramatic 
effect on the CID spectra of the modified peptides as 
briefly reported earlier [20]. 
A detailed study of the CID spectra of peptides that 
have been adducted with either of two diolepoxides, 
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anti-8 aP(9,lO)DE or benzo[ alanthracene-trans- 
8,9-dihydrodiol-lO,ll-epoxide [ anti-BaA(lO,ll)DE] 
(Structure III) is the subject of this investigation. Anti- 
BaP(9,lO)DE adducts with serum albumin have shown 
modification at histidine 1151; therefore, adducts with 
histidine as the site of modification have been used as 
model compounds for the CID tandem mass spectrom- 
etry studies in this work. The term “adduct” refers to 
the covalently modified peptide. Anti-BaP(9,lD)DE is a 
“bay-region” diolepoxide, whereas anti-BaA(lO,ll)DE 
does not belong to this category [21]. A bay-region 
diolepoxide hydrolyzes to form a cation, which is more 
stable than the cation formed from a nonbay-region 
diolepoxide, an effect that is thought to play a role in 
the carcinogenicity of bay-region diolepoxides [22-231. 
Although this article deals with the tandem mass 
spectra of peptides substituted with a PAH trio1 moi- 
ety, it should be noted that mass spectrometric investi- 
gations of reaction products of PAHs [13] with guano- 
sine and amino-PAHs 124, 251 with guanosine and/or 
adenosine have been reported, including their tandem 
mass spectra. 
Materials and Methods 
Benzo[a]pyrene-trans-7,8-dihydrodiol-9,1O-epoxide 
(anti) and benzo[a]anthracene-trans-8,9-dihydrodiol- 
lO,ll-epoxide (anti) were purchased from the National 
Cancer lnstitute Chemical Carcinogen Repository oper- 
ated by Midwest Research Institute (Kansas City, MO). 
All peptides, iodoacetic anhydride, and Z_(N-morph* 
1ino)ethanesulfonic acid (MES) buffer were purchased 
from Sigma Chemical Co. (St. Louis, MO) and used 
without further purification. Dry tetrahydrofuran 
(THF) and trimethylamine (25 wt % aqueous solution) 
were purchased from Aldrich Chemical Co. (Milwau- 
HO 
OH 
II 
kee, WI>. The semipreparative C4 protein reversed- 
phase high-performance liquid chromatography 
(HPLC) column (1 x 25 cm) was purchased from Vy- 
dac Separations Group (Hesperia, CA). 
Mass Spectrometry 
Fast-atom bombardment (FAB) mass spectrometry was 
carried out in the first (MS-l) of two mass spectrome- 
terj of a tandem mass spectrometer (JEOL [Tokyo] 
HXllO/HXllO) operating at an accelerating voltage of 
10 kV and a resolution of 1:lOOO or 1:2600. Single scans 
were acquired at a rate of m/z O-6000 in 1.0 min, with 
lOO-300-Hz filtering and the electron multiplier set at 
1.0 kV. (CsI),CsI+ cluster ions were used for the cali- 
bration. A JEOL Cs+ gun was used at 26 kV. The 
sample (- l-2 nmol in 0.5-yL H,O) was mixed with 
glycerol (0.2 PL) on the probe tip. The volume of the 
sampleeglycerol mixture was reduced by using a vac- 
uum chamber, after which thioglycerol (0.5 PL) was 
added. The probe was then placed into the ion source 
of the mass spectrometer. 
Tandem mass spectrometry was performed on the 
JEOL HXllO/HXllO double focusing tandem mass 
spectrometer, which is of E,B,E,B, configuration. 
Collision-induced dissociation of the protonated pep- 
tide molecule ?C monoisotopic ion) selected with 
MS-l took place in the field-free region after B,. The 
collision cell potential was 3.0 kV and the ion collision 
energies were 7.0 keV. Helium, the collision gas, was 
introduced into the collision chamber to reduce the 
precursor ion signal by 65-70%. The second mass 
spectrometer (MS-21 was scanned from m/z 30 to 20 u 
above the mass-to-charge ratio of the precursor ion by 
using lOO-Hz filtering and a scan rate corresponding to 
m/z 0@6000 in 1.5 min. Two scans were summed for 
each spectrum. MS-2 was operated at 1:1000 resolution 
and was calibrated with a mixture of CsI, NaI, KI, RbI, 
and LiCl [26]. 
Neutral loss scans were performed with MS-1 reso- 
lution set at 1:lOOO by using a grounded collision cell 
located behind the ion source of MS-l. The ion signal 
was reduced by approximately 70% by using helium 
gas. A single scan was acquired with the electron 
multiplier set at 1.5 kV. 
Preparation of PAH-Diolepoxide Adducted 
Synthetic Peptides 
The anti-BaP(9,10)DE-histidine adduct was prepared 
by Day et al. [15]. Adducted peptides were prepared 
as follows. The peptide of interest (25 mg) was dis- 
solved in a minimum volume (2-4 mL) of 0.1-M 
sodium phosphate buffer, pH 7.0, to which was added 
1 mg of the diolepoxide (freshly dissolved in 100.FL 
dry THF). The mixture was incubated rocking for 2 h 
at 37 “C. The product was acidified with acetic acid, 
filtered, and loaded onto a semipreparative (1-X 25- 
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cm) C4 reversed-phase column. The material was 
eluted with a linear gradient of O-60% acetonitiile, 2 
mL/min, in the presence of TFA. The unadducted 
peptide eluted as a very broad peak, after which the 
adducted peptide eluted. The adducted peptide was 
identified by its molecular weight deduced from its 
FAB mass spectrum in the normal mode. 
Preparation of TrimefhyZammoniumacefyl 
Derivatives of anti-Ba P(9,lO)DE 
Adducted Pqtides 
This derivative was prepared by modification of the 
method of Wetzel et al. [271. The peptide (- 10 nmol) 
was dissolved in a 100-PL solution of 1:l 
(buffer:methanol) 0.1-M MES (pH 6.0) and reacted on 
ice with repeated (lo-12 x , 3-min intervals) aliquots 
(0.5% by volume) of the iodoacetic anhydride in THF 
(0.4 M, dry THF, stored desiccated under argon in a 
laboratory freezer). Trimethylamine (25 wt % aqueous 
solution) was added (5% by volume) and allowed to 
react with the iodoacetylated peptide for 30 min at 
room temperature. The reaction was acidified with 
acetic acid, desalted on a short reversed-phase HPLC 
column, and dried in a centrifugal evaporator. The 
peptide was dissolved in water on the day the mass 
spectra were acquired and mixed with thioglycerol 
over a thin layer of glycerol on the probe tip. 
Results and Discussion 
The CID spectra of anti-BaP(9,lO)DE adducted pep- 
tides are dominated by product ions derived from the 
adducting moiety. The CID spectrum of histidine ad- 
ducted at an imidazole nitrogen with anti-BaP(9,lO)DE 
is shown in Figure 1. The stability of the C-10 carbo- 
cation [22, 231 may trigger the heterolytic cleavage of 
the bond between the adduct and the histidine ring 
(Scheme 1). The assignment of the bond to N’ rather 
than N” is made in analogy to earlier work [15]. The 
A 
1 257 . 
I 
F 
CM+H-3023+ 
50 150 250 350 450 
m/z. 
Figure 1. CID tandem mass spectrometry spectrum of the histi- 
dine anti-BaIY9,lO)DE adduct, [M + HI+ = m/z 458.2. 
HzN --+ H2N 
Scheme 1. Mechanism for the production of ions from the 
adducting moiety of anti-BaP(9,lO)DE adducts. An analogous 
mechanism applies for other PAH diolepoxide adducts. The N’ 
adduct is shown in accordance with the finding of earlier work 
on serum albumin adducts [15]. 
resulting ion of m/z 303 then fragments further 
(Scheme 2) to other well stabilized cations, of which 
the smallest, m/z 257, predominates. It should be 
noted that the CID spectra of adducts of I to guanino- 
sine and adeninosine are also dominated by peaks of 
m/z 303,285, and 257 (most abundant) [13]. The peak 
at m/z 156 in Figure 1 corresponds to protonated 
histidine, which is formed by the loss of the trio1 
moiety as an epoxide (i.e., the reverse of the adduct 
formation) as shown in Scheme 3 for a dipeptide. This 
fragmentation is apparently less favored than that de- 
picted in Scheme 1. 
The CID MS/MS spectrum of the anti-BaP(9,lO)DE 
adduct of EGVYVHPV (angiotensin II antipeptide) is 
shown in Figure 2a. The two strongest signals in the 
spectrum, corresponding to m/z 257 and to the ion 
produced from the loss of the adducting moiety as a 
neutral molecule ([M + H - 3q21f), show that cleav- 
age between the anti-BaP(9,lO)DE moiety and its point 
of attachment is the most favored product-ion path- 
way. Charge is retained preferably by the adducting 
moiety as indicated by the greater abundance of the 
m/z 257 ion. As a result of this competition for charge, 
the peptide sequence product ions are of low relative 
abundance. However, from the a: and a; ions, one can 
deduce that the modified amino acid is I-l&6. 
The proposed mechanisms for the genesis of the 
m/z 257 (anti-BaP(9,lO)DE adducting moiety) ion are 
shown in Schemes 1 and 2, respectively; the mecha- 
nisms for the adducted peptide [M + HI+ ion minus 
the adducting moiety are shown in Scheme 3. The 
peptide molecular ion (m/z 900.1) that lacks the anti- 
BaP(9,lO)DE moiety fragments further, giving rise to a 
spectrum that is a superposition of ions derived from 
adducted as well as unadducted peptides. 
Other PAH diolepoxide adducts to peptides simi- 
larly exhibit dominant fragment ions that represent 
this moiety (Scheme 2) and depress the formation of 
the sequence characteristic peptide fragments. For ex- 
ample, adducts of anti-BaA(lO,ll)DE (II) exhibit an 
abundant fragment ion at m/z 233 (Figure 2~). The 
same holds for adducts of fluoranthene-diolepoxide 
[18], which give rise to an ion of m/z 207. This peak 
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OH OH OH 
m/z 285* L -H20 
*Or positional 
isomer 
m/z 267* 
Scheme 2. Pathway that produces ions from the anti-BaPf9,lO)DE moiety 
dominates the region of the spectrum shown in ref 18, 
but it was neither labeled nor discussed. 
The peptide sequence fragment ions in the spec- 
trum of anti-BaP(9,lO)DE adducted DRVYIHPF (Fig- 
ure Zb) [20] are more abundant, relative to the m/z 
257 ion, than for EGVYVHPV (Figure 2a). The a:-ag 
ions indicate that the PAH trio1 is attached to Hisd. 
Furthermore, the spectrum contains a complete series 
of a?-as ions. Both of these improved features are 
probably due to the presence of arginine near the 
N-terminus of the former peptide. This strongly basic 
amino acid localizes the charge and increases the 
abundance of N-terminal product ions. At the same 
time, this charge localization favors the loss of the 
adducting moiety as a neutral species, thus giving rise 
to more abundant peptide fragment ions. As expected, 
the CID spectrum of the anti-BaA(lO,ll)DE adduct 
exhibits very similar features (Figure 24. However, the 
lower relative abundance of the m/z 233 ion implies 
that cleavage of the adductkpeptide bond with reten- 
tion of charge by the adducting moiety is less favored 
for the nnti-BaA(lO,ll)DE moiety. Note that anti- 
BnA(lO,ll)DE lacks the bay-region resonance stabiliza- 
tion at C-11 that is known to stabilize a positive charge 
Hf H+ 
?I T 8 
I I I 
.CH, N 
3 F R 
%N C t 3 b? OH + H2N’ 
CH, 4 .c 
b: \ 
C i 3 CH OH 
b: \ 
OH OH product ions 
Scheme 3. Mechanism for the production of ions from the 
peptide portion of anti-BaP(9,lO)DE adducts. An analogous 
mechanism applies for other PAH diolepoxide adducts. 
m/z 257* 
2. CID tandem mass spectra of (a) anti-BnP(9,lO)DE 
adducted KVYVHPV, [M + HI+= m/z 1202.5 (insert: 1X-fold 
expansion of y-axis from m/z 920-1080); (b) anti-BaP(9,lO)DE 
adducted DRVYIHI’F, [M + HI+ nr/t = 1348.6 (insert: 7.5fold 
expansion of y-axis from m/z 1050-1300); Cc) anti-BaA(lO,ll)DE 
adducted DRVYIHPF, [M + HI+= m/z 1324.8. In this and all 
other figure legends, the modified amino acid is indicated in 
bold. Product ions that contain the adducting moiety are labclcd 
with an asterisk. 
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at the analogous C-10 on anti-BaP(9,lO)DE [21]. Quan- 
tum mechanical calculations show that the cations pro- 
duced by the hydrolysis of bay-region diolepoxides are 
more stable cations than those from nonbay-region 
diolepoxides [21-231. The very small peaks labeled a*,, 
d& [28], and a: indicate that a minor by-product, 
probably the N-terminal anti-BaA(lO,ll)DE adduct, 
was formed during the synthesis. The notation d,, and 
d, for amino acids with an unsymmetrically substi- 
tuted barbon is analogous to that for w, and w,,, 
ions [28]. 
As Figures 2b and 2c indicate, localization of the 
charge on the peptide moiety increases the relative 
abundance of sequence characteristic peptide ions. It is 
by now well known 127, 29-311 that placing a fixed 
charge on either end of a peptide further directs the 
fragmentation process and that a positive charge local- 
ized at the N-terminus is most effective. For this pur- 
pose, a trimethylammonium acetyl (TMAA) group is 
the optimal choice [27, 29, 301. 
The spectrum of anti-BaP(9,lO)DE adducted 
TMAA-EGVYVHPV (Figure 3a) exhibits complete a, 
and d, ion series (except for glycine). The peptide 
product ions, particularly the important a$, a:, and a: 
fragments, are far more abundant than those observed 
in the CID spectra of PAH adducted peptides that do 
not bear a fixed charge (Figure Za). The m/z 257 ion is 
still abundant but no longer dominates the spectrum. 
The product ions shifted by 302 u due to the adduct 
of I are marked with an asterisk. As was observed 
with the underivatized peptide adducts, two processes 
operate to give rise to superposition of two sets of 
1021 6 
CM-3021+ 
Figure 3. CID tandem mass spectra of (a) the trimethyl- 
ammoniumecyl 0MA.A) derivative of anti-BaP(9,lO)DE ad- 
ducted EGVYVHPV, [Ml+ = m/z 1300.9; (b) the TMAA deriva- 
tive of anti-BaN9,lO)DE adducted VHLTPVEK, [Ml+ = m/z 
1323.8. Product ions that contain the adducting moiety are la- 
beled with an asterisk. [Ml+ denotes the precursor cation. 
I , 899.4. 
J 
Figure 4. Constant neutral loss scan (302 u) indicating that the 
precursor ion is m/z 1201.4, which is in good agreement with 
anSBaP(9,lO)DE adducted EGVYVHPV, [M + HI+ = m/z 
(calculated) 1201.9. 
sequence ions: one set is derived from the actual pre- 
cursor ion of the adduct; the other set is derived from 
the precursor ion after loss of the diolepoxide moiety 
as a neutral molecule (analogous to Scheme 3). The 
m/z 257 ion may arise through formation of a zwitteri- 
onic peptide (i.e., leaving a negative charge on the 
imidazole ring) because the quaternary ammonium 
cation is immobile (analogous to Scheme 1). Similar 
results were obtained for the spectrum of anti- 
BaP(9,lO)DE adducted TMAA-Vl-lLTPVIX (Figure 3b). 
For the sake of convenience, these TMAA derivatives 
were prepared at the lo-nmol level for this study of 
fragmentation behavior. For unadducted peptides, it 
has been shown that the derivatization procedure can 
be applied to as little as 100 pmol and that a fraction 
corresponding to 40 pmol of the product still resulted 
in CID spectra with high signal-to-noise ratio [32]. 
Because the CID spectra of all adducts exhibit a 
strong signal that corresponds to the loss of the ad- 
ducting moiety as a neutral molecule (e.g., 302 u from 
nnfi-BaP(9,lO)DE adducted peptides; see Scheme 31, all 
peptides with this modification can be detected by a 
302-u constant neutral loss scan. The result for anti- 
BaP(9,lO)DE adducted EGVYVHPV, [M + HI+= m/z 
1201.4, is shown in Figure 4. Although this spectrum 
was obtained with l-2 run01 of sample, as little as 50 
pmol still would result in a signal-to-noise ratio of 3:l. 
Such scans have been very useful in the screening of 
proteolytic digests for adducted peptides by using any 
of several diolepoxide metabolites, including isomers 
of BnA(lO,ll)DE, benzo[a]anthracene-fnzns-3,4-dihy- 
drodiol-1,2_epoxide (anti), and benzol b]fluoranthene- 
truns-9,10-dihydrodiol-11,12-epoxide (anti) [33]. 
Conclusions 
CID spectra of peptides adducted with PAH diolepox- 
ide metabolites are dominated by ions produced from 
cleavage of the bond between the adducting moiety 
and the adducted side chain. When charge is retained 
by the adducting moiety, an abundant ion is observed 
at m/z 257 for anti-BuP(9,lO)DE adducted peptides 
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and m/z 233 for anti-BaA(lO,ll)DE adducted pep- 
tides. The ion produced by loss of the adducting moi- 
ety as a neutral species and corresponding to the 
mass-to-charge ratio value of the unadducted peptide 
[M + HI+ ion is usually less abundant. The loss of the 
metabolite moiety is quite useful for identifying ad- 
ducted peptides by using constant neutral loss scans. 
The abundance of the metabolite ion reduces the inten- 
sity of peptide fragment ion signals, but conversion of 
the adducted peptides to their trimethylammonium- 
acyl derivatives is useful for increasing the abundance 
of peptide fragment ions. 
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